Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Before investing in cryptocurrency, it's important to be informed. Discover key insights that every investor should know.
18,573 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
As AI-driven gains fade in 2026, investors face a choice on covered call ETFs. This piece breaks down performance, ri...
Investors brace for potential disruption as Trump-Iran brinkmanship over the Strait of Hormuz raises the risk of oil ...
Fintech down this year has pressured growth equities, yet cybersecurity ETFs are delivering relative steadiness as co...
Today’s move in redwire stock popped today reflects a developing narrative around space infrastructure and NASA's new...
Bluesky is carving a new path in social media by using an open, federated protocol. This article explains what Bluesk...
Quant funds are piloting a data-pruning approach named test delete to improve backtest robustness as markets remain v...
Policymakers are weighing tax shifts that could touch luxury spending by the ultra-wealthy. Investors watch designer ...
KBWY remains a high-yield ETF, but payout sustainability is at risk as cannabis REIT tenants face cash-flow headwinds...
A hypothetical $1,000 XRP bet on election night would have endured wild swings and sharp turns. Here’s the latest rea...
NVIDIA stakes its AI dominance on data center hardware while Palantir expands software driven growth, setting up a hi...
Huntington & Ellis launches Smart by h&e, an in-house AI assistant designed to streamline deals, draft communications...